AKERO THERAPEUTICS INC. - COMMON STOCK

Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants

28 Jan 2025 21:30:00 By Nasdaq GlobeNewswire

Akero Therapeutics Announces Proposed Public Offering of Common Stock

27 Jan 2025 16:01:00 By Nasdaq GlobeNewswire

Akero Therapeutics Reports Preliminary Topline Results Showing Statistically Significant Reversal of Compensated Cirrhosis (F4) Due to MASH—by Both Completer and ITT Analyses—at Week 96 in Phase 2b SYMMETRY Study

27 Jan 2025 06:30:00 By Nasdaq GlobeNewswire

Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH

24 Jan 2025 16:05:00 By Nasdaq GlobeNewswire

Akero Therapeutics Completes Enrollment of the Double-Blind Portion of the Phase 3 SYNCHRONY Real-World Study Evaluating Efruxifermin (EFX) in Patients with Non-Invasively Diagnosed MASH or MASLD

13 Jan 2025 07:00:00 By Nasdaq GlobeNewswire

Akero Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

07 Jan 2025 07:00:00 By Nasdaq GlobeNewswire

Akero Therapeutics to Present at the 7th Annual Evercore ISI HealthCONx Conference

26 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Akero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting® 2024

15 Nov 2024 11:00:00 By Nasdaq GlobeNewswire

Akero Therapeutics to Present at the Jefferies London Healthcare Conference

13 Nov 2024 16:05:00 By Nasdaq GlobeNewswire

Akero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

08 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024

21 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference

30 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Akero Therapeutics Announces First Patient Dosed in Phase 3 SYNCHRONY Outcomes Study of Efruxifermin in Patients with Compensated Cirrhosis Due to MASH

09 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Akero Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

28 Aug 2024 16:05:00 By Nasdaq GlobeNewswire

Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

09 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Akero Therapeutics Announces Initiation of Phase 3 SYNCHRONY Outcomes Trial of Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH

11 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

Akero Therapeutics Presents Poster and Late-breaking Oral Presentation on EFX at the EASL Congress 2024

08 Jun 2024 08:15:00 By Nasdaq GlobeNewswire

Akero Therapeutics to Present at the Jefferies Global Healthcare Conference

29 May 2024 07:00:00 By Nasdaq GlobeNewswire

Akero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

10 May 2024 07:00:00 By Nasdaq GlobeNewswire

Akero Therapeutics to Present at the BofA Securities 2024 Health Care Conference

08 May 2024 07:00:01 By Nasdaq GlobeNewswire